TNF and idiopathic pulmonary fibrosis: In several multi-center clinical trials, anti-inflammatory drugs (prednisone, TNF-α)or immunomodulators (IFNγ, simtuzumab) failed to improve lung function, control disease progression, or improve survival in IPF.